Navigation Links
Amerigen Pharmaceuticals and the Shanghai Fosun Omni Pharmaceutical Company Enter Into Collaboration Agreement for the Development of Generic Oral Controlled Release Products
Date:1/11/2012

EAST BRUNSWICK, N.J. and SHANGHAI, Jan. 11, 2012 /PRNewswire/ -- Amerigen Pharmaceuticals Limited ("Amerigen") and the Shanghai Fosun Omni Pharmaceutical Co., Ltd ("Fosun Omni") today announced they had entered into a collaboration agreement regarding the development of generic oral controlled release products. Under the terms of the agreement, Fosun Omni will use its formulation expertise to develop products for Amerigen to commercialize in the United States and other territories. On signing the agreement, Fosun Omni received an up-front fee with respect to the first product and is eligible for additional product-specific development milestones and royalties on any commercialized products.

"This collaboration allows Amerigen to add further momentum to its efforts to build a portfolio of differentiated, high value generic pharmaceuticals," said Jonathan Embleton, Chief Business Officer for Amerigen. "Omni's internationally experienced scientific team will develop complex oral controlled release formulations for scale-up and commercial manufacture at Amerigen's FDA approved facility in Suzhou, which is only a two hour drive from Fosun Omni's operating base in Shanghai's Zhangjiang Hi-Tech Park.

CSO of the Fosun Omni, Dr Ping He, commented, "This collaboration with Amerigen continues Fosun Pharma's strategy to develop some difficult ANDA products to FDA and to speed up the product commercialization process for our partners. This is the first step of the collaboration."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese SFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

About Fosun Omni
Shanghai Fosun Omni Pharmaceutical Co., Ltd is a global pharmaceutical company devoted to development, out-licensing, formulation CRO services, and independent R&D for NDA and ANDA projects.  The company focuses are those difficult to develop, manufacture, and replicate oral solid formulations for regulated market and China market at highly competitive prices.


'/>"/>
SOURCE Amerigen Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
2. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
3. E7: The Outlook for Pharmaceuticals to 2012
4. Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes
5. The Outlook for Pharmaceuticals Worldwide
6. Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza®
7. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
8. KalVista Pharmaceuticals and JDRF Form Research Partnership Focused on Novel Approach for Treating Diabetic Eye Disease
9. Questcor Pharmaceuticals Reports Strong Finish to 2011
10. Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
11. Radient Pharmaceuticals Announces New Advertisement for Oncology Publications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... BERLIN , April 29, 2016 ... world-leading glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years ... pharmaceutical and biotechnology industries. His last role was at ... Member of the Executive Board. Previously Dr. Zurlo held ...
(Date:4/28/2016)... 2016  Marking its one year anniversary since ... cancer risk test, Color Genomics announced ... highly impact the most common hereditary cancers affecting ... Test analyzes hereditary cancer risks for breast, colorectal, ... The Color Test is physician ordered and includes ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... , ... April 29, 2016 , ... On Tuesday, April ... across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the ... Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations which ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce ... stability, even security. Most importantly, employees are the single most important asset in ... workers so unhappy? , Just under half of American workers are emotionally checked ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
Breaking Medicine News(10 mins):